CD274 and non-small cell lung carcinoma: Another systemic analysis similarly presented that 16% (versus 14% with PD-L1 inhibitors) of NSCLC patients receiving PD-1 inhibitors experienced imADEs, and 4% (versus 2% with PD-L1 inhibitors, p < 0.05) developed pneumonitis [37].